Combination therapy for malaria: Mission accomplished? Editorial commentary

Clinical Infectious Diseases (Impact Factor: 9.42). 05/2007; 44(8):1075-7. DOI: 10.1086/512743
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Malaria is a significant cause of morbidity and mortality in the developing world. Until recently malaria was winning but with increase in funding particularly from philanthropic groups the ability to control malaria is again possible. There are still many challenges to developing the next generations of anti-malarials. This article will briefly discuss the challenges and the advance that are being made.
    Current Opinion in Microbiology 10/2008; 11(5):428-33. DOI:10.1016/j.mib.2008.09.003 · 7.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nine dihydroartemisinin acetal dimers (6-14) with diversely functionalized linker units were synthesized and tested for in vitro antiprotozoal, anticancer and antimicrobial activity. Compounds 6, 7 and 11 [IC(50): 3.0-6.7 nM (D6) and 4.2-5.9 nM (W2)] were appreciably more active than artemisinin (1) [IC(50): 32.9 nM (D6) and 42.5 nM (W2)] against the chloroquine-sensitive (D6) and chloroquine-resistant (W2) strains of the malaria parasite, Plasmodium falciparum. Compounds 10, 13 and 14 displayed enhanced anticancer activity in a number of cell lines compared to the control drug, doxorubicin. The antifungal activity of 7 and 12 against Cryptococcus neoformans (IC(50): 0.16 and 0.55 microM, respectively) was also higher compared to the control drug, amphotericin B. The antileishmanial and antibacterial activities were marginal. A number of dihydroartemisinin acetal monomers (15-17) and a trimer (18) were isolated as byproducts from the dimer synthesis and were also tested for biological activity.
    Bioorganic & medicinal chemistry 12/2009; 17(23):7949-57. DOI:10.1016/j.bmc.2009.10.019 · 2.95 Impact Factor